<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Eurocord Transplant has established a registry for studying results of cord blood transplant </plain></SENT>
<SENT sid="1" pm="."><plain>We have analyzed 78 patients who have received a related CBT between October 1988 and December 1996 </plain></SENT>
<SENT sid="2" pm="."><plain>The median follow-up time was 29 months (1-99) </plain></SENT>
<SENT sid="3" pm="."><plain>The median age was 5 years (0.2-20), median weight 19 kg (5-50) </plain></SENT>
<SENT sid="4" pm="."><plain>Forty-six patients had a malignant disease: 32 <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> (AL), six <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>), four <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, two <z:hpo ids='HP_0003006'>neuroblastoma</z:hpo> and two non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Thirty-two patients were transplanted for non-malignant diseases including 17 <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo> syndromes (BMFS), three sickle cell <z:hpo ids='HP_0001903'>anemia</z:hpo>, five <z:e sem="disease" ids="C0039730" disease_type="Disease or Syndrome" abbrv="">thalassemia</z:e> and seven inborn errors </plain></SENT>
<SENT sid="6" pm="."><plain>The donor was an HLA-identical sibling in 60 cases and an HLA-mismatched donor in 18 cases </plain></SENT>
<SENT sid="7" pm="."><plain>As conditioning, 36 patients received irradiation and 40 patients received associated <z:chebi fb="0" ids="28901">busulfan</z:chebi>-containing regimens </plain></SENT>
<SENT sid="8" pm="."><plain>GVHD prophylaxis consisted of CsA alone in 36 cases, CsA associated with <z:chebi fb="0" ids="8382">prednisone</z:chebi> in eight cases, CsA, <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (Mtx) with or without <z:chebi fb="0" ids="8382">prednisone</z:chebi> in 28 cases and CsA with monoclonal antibody or ATG in four cases </plain></SENT>
<SENT sid="9" pm="."><plain>The median number of nucleated cells (NC) infused/kg was 3.9 x 10(7) (0.7-15) </plain></SENT>
<SENT sid="10" pm="."><plain>One-year survival was 63 +/- 6% </plain></SENT>
<SENT sid="11" pm="."><plain>Age, weight, HLA identity and negative cytomegalovirus (CMV) serology in the recipient were significant favorable prognostic factors </plain></SENT>
<SENT sid="12" pm="."><plain>Among these 78 patients, the incidence of grade &gt; or = II GVHD was 9% in HLA-matched CBT and 50% in mismatched CBT (P &lt; 0.001) </plain></SENT>
<SENT sid="13" pm="."><plain>Neutrophil engraftment was associated with age &lt;6 years (P = 0.02) and weight &lt;20 kg (P = 0.02) </plain></SENT>
<SENT sid="14" pm="."><plain>It was 73% in patients receiving &lt;3.7 x 10(7) nucleated cells (NC) infused/kg and 85% in patients receiving more (P = 0.06) </plain></SENT>
<SENT sid="15" pm="."><plain>Favorable factors for platelets engraftment were age &lt;6 years (P = 0.03), weight &lt;20 kg (P = 0.002) and HLA identity (P &lt; 0.0001) </plain></SENT>
<SENT sid="16" pm="."><plain>Related cord blood transplantation offers a good alternative to BMT </plain></SENT>
<SENT sid="17" pm="."><plain>Theses results are in favor of freezing cord blood in families in whom a transplant might be indicated </plain></SENT>
</text></document>